Indication

Sensorineural hearing loss associated with biallelic OTOF mutations

Sensorineural hearing loss associated with biallelic *OTOF* mutations is an autosomal recessive, nonsyndromic auditory disorder characterized by prelingual, typically severe-to-profound bilateral hearing impairment. Read more about Sensorineural hearing loss associated with biallelic OTOF mutations

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Sensorineural hearing loss associated with biallelic OTOF mutations therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Sensorineural hearing loss associated with biallelic OTOF mutations preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Sensorineural hearing loss associated with biallelic OTOF mutations.

Sensorineural hearing loss associated with biallelic *OTOF* mutations is an autosomal recessive, nonsyndromic auditory disorder characterized by prelingual, typically severe-to-profound bilateral hearing impairment.

It affects the peripheral auditory system, specifically presenting as an auditory synaptopathy or auditory neuropathy spectrum disorder (ANSD).

Pathophysiologically, loss-of-function variants in both alleles of the *OTOF* gene disrupt the synthesis of otoferlin, a calcium sensor protein essential for synaptic vesicle exocytosis and neurotransmitter release at the ribbon synapses of cochlear inner hair cells.

Clinically, affected individuals demonstrate absent or severely abnormal auditory brainstem responses alongside preserved outer hair cell function, as evidenced by intact otoacoustic emissions or cochlear microphonics.

Personalize your experience

Follow Sensorineural hearing loss associated with biallelic OTOF mutations and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it